OBJ reduces delivery time
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 15 February, 2005 - 21:00
AN independent scientific study has shown that OBJ’s electronic drug delivery technology has reduced drug delivery times up to 70 per cent.
In the same study, conducted by the Western Australian Biomedical Research Institute, OBJ’s technology was shown to reduce the time to onset of action and the time to achieve specific drug levels.
The drugs being delivered were prilocaine and lignocaine hydrochloride, both local anaesthetic drugs that penetrate skin poorly.
OBJ’s is now awaiting Ethics Committee approval for human trials and will expand its drug testing program to include a range of anti-cancer drugs, human hormones and cosmetic compounds used in anti-ageing and anti-scarring applications.